Skip to main content
Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients

Fig. 1

Treatment response, overall survival probability, long-term prognosis and CAR T-cells persistence. A Clinical outcomes of patients treated with CD19/CD22 CAR T-cells. Clinical outcomes, treatment response of each patient after CD19/CD22 CAR T-cell therapy and the duration of response. Patient number is shown to the left. B–C Survival analysis. OS and LFS from the day of CAR T-cells infusion are shown for patients who received FC lymphodepletion with DAC (DAC, n = 14) compared with those who received FC alone (CON, n = 12). D–E Survival analysis of 4 subgroups. The OS and LFS were prolonged by allo-HSCT in all subgroups. F The expansion and persistence of CAR T-cells. The presence of CD19/CD22 CAR T-cells in the peripheral blood as assessed by quantitative real-time polymerase chain reaction (PCR) assay. Time points after a second CAR T-cells infusion or allo-HSCT are excluded. We analyzed the kinetics of CAR T-cell counts by using LOESS (Local Polynomial Regression) curve fitting. Bold line represents the averaged data using LOESS curve fitting approximation with the standard error in grey

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us